Needle Free Injectors Market Is Expected To Reach A Revenue Of USD 2,980.9 Million By 2033, At 8.1% CAGR: Dimension Market Research

New York, Nov. 11, 2024 (GLOBE NEWSWIRE) -- market Overview

The Global Needle Free Injectors Market is projected to grow from USD 1,478.9 Million in 2024 to USD 2,980.9 Million by 2033, at a CAGR of 8.1% .

These injectors deliver medications and vaccines without traditional needles, using high-pressure technology to penetrate the skin, reducing pain and needle-related risks. They are used for insulin delivery, vaccinations, and growth hormone administration. The adoption of advanced drug delivery technologies is driving market growth.

The US Needle-Free Injectors Market

In the US, the needle-free injectors market is expected to grow from USD 645.6 million in 2024 to USD 1,249.0 million by 2033, at a CAGR of 7.6% .

The increasing prevalence of diabetes and cancer, demand for painless drug delivery methods, patient comfort, regulatory support for innovative medical devices, and the shift toward home-based healthcare are fueling this growth. Technological advancements are also enhancing the appeal of needle-free injectors among patients and healthcare providers.

Click to Request Sample Report and Drive Impactful Decisions:

Important Insights

• Market Expansion: The global needle-free injectors market is projected to grow by USD 1,394.7 million , with a CAGR of 7.8% from 2025 to 2033.
• Product Leadership: Fillable injectors are expected to lead the global market with the highest revenue share in 2024.
• Technology Dominance: Gas-powered technology is anticipated to dominate the global market in 2024, holding a significant revenue share of 36.0% .
• Usability Analysis: The reusable segment is forecasted to command a substantial share of the needle-free injector market in 2024.
• Type Overview: Liquid-based injectors are predicted to achieve the highest revenue share in the global market for needle-free injectors in 2024.
• Application Insights: Vaccine delivery is projected to be a leading application segment in the global needle-free injectors market in 2024.
• Delivery Site Analysis: Subcutaneous delivery sites are expected to dominate the market, accounting for 50.9% of the revenue share in 2024.
• End User Overview: Hospitals are set to lead the global needle-free injectors market in revenue terms, with a 47.9% share in 2024.
• Regional Analysis: North America is predicted to dominate the global needle-free injectors market, holding the highest market share of 51.3% in 2024.

Latest Trends

• Needle-free injection technology is now utilized in veterinary medicine and cosmetic procedures, expanding beyond traditional hospital settings. This broader application has significantly increased the demand for needle-free injectors in the healthcare, cosmetic, and veterinary industries.
• The growing prevalence of diabetes and the need for more patient-friendly administration methods are driving the adoption of needle-free injectors. It improves patient compliance and reduces needle phobia among diabetic patients.

Competitive Landscape

• Major market players are innovating their products and engaging in mergers and acquisitions to enhance their product portfolios and maintain competitiveness.
• Key companies in the needle-free injectors market include Gerresheimer AG, Pfizer Inc., Halozyme, CSL Limited (Seqirus UK Limited), Crossject, Portal Instruments, Ferring Pharmaceuticals, PharmaJet Inc., and PenJet Corporation. These players are focusing on expanding their brands into emerging regions and updating their product offerings.
• Manufacturers are employing various expansion strategies, including acquisitions, new product launches and approvals, agreements, partnerships, and collaborations to strengthen their market position.

Some of the prominent market players:

• PharmaJet
• Crossject
• Portal Instruments
• NuGen Medical Devices
• Inovio Pharmaceuticals
• Antares Pharma, Inc
• Aijex Pharma International Inc.
• Ferring B.V.
• Penjet Corporation
• Medical International Technology Inc.
• Other Key Players

Transform your business approach with strategic insights from our report. Get in touch to request our brochure today! :

Needle-Free Injectors Market Scope

Market Analysis

Gas-powered needle-free injectors are projected to lead the market with a 36.0% share by 2024, thanks to their versatility spanning transdermal, subcutaneous, and intramuscular applications.

Gas-powered injectors' popularity stems from improved dosage accuracy, rapid drug delivery speed, and faster patient responses as well as greater drug diffusion into tissues - key features required in both routine and emergency healthcare scenarios.

Purchase the Competition Analysis Dashboard Today:

Global Needle-Free Injectors Market Segmentation

By Product

• Fillable
• Prefilled

By Technology

• Spring-based Injectors
• Gas-powered Injectors
• Laser-powered Injectors
• Vibration-based Injectors

By Usability

• Reusable
• Disposable

By Type

• Liquid-based Needle Free Injectors
• Powder-based Needle Free Injectors
• Projectile/depot-based Needle Free Injectors

By Application

• Vaccine Delivery
• Insulin Delivery
• Pain Management
• Others

By Delivery Site

• Subcutaneous
• Intramuscular
• Intradermal

By End User

• Hospitals
• Clinics
• Home Care Settings
• Research Laboratories
• Others

Drivers

• The needle-free injector market presents a convenient, painless alternative to traditional needle-based methods for medication delivery. These devices are used to treat various conditions and are expected to grow due to the increasing prevalence of chronic diseases like osteoporosis and diabetes.
• They provide a pain-free option compared to traditional needles, benefiting patients who are needle-phobic or experience discomfort. The rise in patient preference for painless drug delivery systems contributes to the market's growth.

Restraints

• Concerns about the effectiveness, safety, and reliability of these devices may hinder their acceptance among healthcare providers and patients, thus, restraining the growth of this market.
• Needle-free injectors typically have a higher cost compared to conventional needle-based systems. The initial investment and ongoing maintenance costs can limit their use, particularly in low-income areas or budget-constrained healthcare settings, which could impede market growth.

Opportunities

• Government initiatives to advance healthcare systems are boosting demand for needle-free injectors. These initiatives aim to increase adoption in households, hospitals, and independent laboratories, presenting growth opportunities for the market.
• Investment in research and development is expected to be a key growth driver for the needle-free injectors market, supported by both developed and emerging economies.
• Ongoing advancements in medical device technology and innovations in product design are creating opportunities for the growth of the market.

Regional Analysis

North America is predicted to lead the needle-free injectors market with a revenue share of 51.3% by 2024, due to an abundance of major market players located there as well as rising chronic & lifestyle-related disease incidence. Further, self-administration of medications within both North America & Canada should propel market expansion in these two regions.

Asia-Pacific should experience rapid expansion during its forecast period due to rapidly developing healthcare sectors like those found in China & India combined with rapidly rising life expectancies, rising per capita income levels, as well as investments made by key market participants such as key market players from major market players in these two markets.

Click to Request Sample Report and Drive Impactful Decisions:

By Region

North America

• The U.S.
• Canada

Europe

• Germany
• The U.K.
• France
• Italy
• Russia
• Spain
• Benelux
• Nordic
• Rest of Europe

Asia-Pacific

• China
• Japan
• South Korea
• India
• ANZ
• ASEAN
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa
• Israel
• Egypt
• Rest of MEA

Browse More Related Reports

• Personalized Medicine Biomarker Market size is expected to reach a value of USD 17.0 billion in 2024, and it is further anticipated to reach a market value of USD 72.7 billion by 2033 at a CAGR of 17.5%.
• Nutraceutical Excipients Market size is expected to reach a value of USD 5.2 billion in 2024, and it is further anticipated to reach a market value of USD 10.0 billion by 2033 at a CAGR of 7.6%.
• Next Generation Sequencing Market size is expected to hold a market value of USD 13.5 billion in 2024 and is projected to show subsequent growth with a market value of USD 92.2 billion by the end of 2033 at a CAGR of 23.8%.
• Monoclonal Antibodies Market size is expected to reach a value of USD 279.8 billion in 2024, and it is further anticipated to reach a market value of USD 804.7 billion by 2033 at a CAGR of 12.5%
• Medical Engineered Material Market is expected to dominate with USD 23.9 billion in 2024 and is anticipated to grow to USD 82.9 billion by 2033 at a CAGR of 14.8 %.
• Electrosurgical Generator Market is expected to reach a valuation of USD 1.8 billion in 2024 and is anticipated to achieve a remarkable CAGR of 8.0% for the forecast period to reach a value of 3.7 billion in 2033.
• Fabry Disease Treatment Market size is expected to value USD 2.4 billion in 2024 and reach a market value of USD 4.9 billion in 2033 at a CAGR of 8.3%.
• Hearth Market is expected to value USD 13.6 billion in 2024, and it is further anticipated to reach a market value of USD 24.5 billion by 2033 at a CAGR of 6.8 %.
• Sinus Dilation Devices Market size is estimated to reach a value of USD 3.5 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 10.0% for the forecasted period (2024-2033).
• Companion Diagnostics Market size was valued USD 8.0 billion in 2023 which is further expected to reach a market value of USD 26.0 billion in 2033 at a CAGR of 12.5%.

Recent Developments

• In September 2023, PharmaJet, known for its precision delivery systems, reported successful outcomes from Scancell's Phase 2 clinical trial. The trial used PharmaJet's Stratis System for needle-free injections to treat patients with unresectable advanced melanoma, a method preferred by patients.
• In September 2023 , the Indian government introduced GEMCOVAC-OM, an mRNA-based COVID-19 booster vaccine specifically designed for Omicron variants. Administered intradermally with a needle-free injector, this thermostable vaccine demonstrated stronger immune responses in study participants.
• In August 2023 , Pulse NeedleFree Systems launched a range of disposable needle-free vaccination equipment for animals which offers cost-effective health and food safety benefits for pig farmers, comparable to traditional syringes and needles.
• In June 2023 , PharmaJet collaborated with Zydus Lifesciences to deliver the world's first plasmid DNA COVID-19 vaccine using its Tropis system, which has been shown to improve immune response and clinical effectiveness.
• In March 2022 , NovaXS Biotech secured investor backing for its patented needle-free injector. The device features a cloud-based platform that collects patient data, including injection time, frequency, dosage volume, and medication temperature, to assist physicians in evaluating the effects of the dosage on the patient.

About Dimension Market Research (DMR)

Dimension Market Research (DMR) is a market research and consulting firm based in India & US, with its headquarters located in the USA (New York). The company believes in providing the best and most valuable data to its customers using the best resources analysts into work, to create unmatchable insights into the industries, and markets while offering in-depth results of over 30 industries, and all major regions across the world.

We also believe that our clients don't always want what they see, so we provide customized reports as well, as per their specific requirements to create the best possible outcomes for them and enhance their business through our data and insights in every possible way.

MENAFN11112024004107003653ID1108873069